Furthermore, a dose-dependent inhibition of ZEB1 protein levels was confirmed in MDA-MB-231 and SUM-159 breast cancer cells in response to treatment with 50–150 μM biochanin A (Supplementary Fig. S1b). This evidence concerns the gene ZEB1 and breast carcinoma.